Small-Interfering RNA Olpasiran and Apolipoprotein B Particles
This secondary analysis of the OCEAN(a)-DOSE randomized clinical trial investigates the effect of the small-interfering RNA olpasiran on atherogenic lipoproteins.
Authors
- J. Antonio G. López (ORCID: https://orcid.org/0000-0001-8604-5549)
- Helina Kassahun
- Marc S. Sabatine (ORCID: https://orcid.org/0000-0002-0691-3359)
- Huei Wang (ORCID: https://orcid.org/0000-0002-9903-1979)
- Seth J. Baum (ORCID: https://orcid.org/0000-0003-1202-8126)
- Michelle L. O’Donoghue (ORCID: https://orcid.org/0000-0002-8663-0067)
- André Zimerman (ORCID: https://orcid.org/0000-0001-8977-6929)
- You Wu (ORCID: https://orcid.org/0000-0003-4537-6530)
- Daniel Gaudet (ORCID: https://orcid.org/0000-0002-5185-3666)
- Jingying Wang (ORCID: https://orcid.org/0000-0002-9766-2769)
- Robert S. Rosenson
- Jeong-Gun Park
Institutions
- Université du Québec à Chicoutimi (CA)
- Brigham and Women's Hospital (US)
- Amgen (United States) (US)
- Hospital Moinhos de Vento (BR)
- Thrombolysis in Myocardial Infarction Study Group (US)
- Florida Atlantic University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- JAMA Cardiology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1001/jamacardio.2025.4105
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00